A subscription to JoVE is required to view this content. Sign in or start your free trial.
The present protocol provides a detailed description of a percutaneous dual lumen right ventricular assist device and illustrates step-by-step instructions on the safe implanting, managing, and removing the device. Guidance on its use and troubleshooting complications from one of the most significant single-center experiences is also included.
Right ventricular (RV) shock, classically characterized by elevated central venous pressure (CVP) with normal to low pulmonary artery (PA) and pulmonary capillary wedge pressures (PCWP), remains a significant cause of morbidity and mortality worldwide if left untreated. Therapies for the treatment of RV shock range from medical management to durable or percutaneous mechanical circulatory support (MCS). A unique MCS device, a percutaneous right ventricular assist device (pRVAD), approved for use by the Food and Drug Administration (FDA) in 2014, works by temporarily off-loading the RV through a single, dual lumen catheter with extracorporeal mechanical support and is capable of shunting blood from the right atrium (RA) to the main PA. Although initially approved as venous-venous extracorporeal membrane oxygenation (VV-ECMO) device, this work will focus on the use of RV support, as ambulatory VV-ECMO strategies have been described previously. The catheter is most commonly inserted through the right internal jugular (IJ) vein into the PA and connected to an external pump, allowing flow up to 5 L/min. This device may be an attractive choice for the treatment of RV shock due to its percutaneous, minimally invasive insertion and removal and its ability to allow patient ambulation while the device is in place. This protocol discusses in detail the equipment, hemodynamic effects, indications, contraindications, complications, currently available research in the literature, and step-by-step instructions on how to implant, manage, and extract the device, along with the guidance on use and troubleshooting complications from one of the largest, single-center experiences with the device.
Cardiogenic shock (CS) from right ventricular (RV) failure remains one of the most challenging cardiac pathologies to manage and portends high mortality and morbidity1. There are three primary pathologic states which may result in RV failure: loss of myocardial contractility, volume overload, and pressure overload2. After a heart transplant, loss of RV contractility can be secondary to myocardial ischemia, infarction, or inflammation caused by myocarditis or primary graft dysfunction3. RV volume overload may be secondary to right-sided valvular insufficiency, shunting, or inadequate....
The present protocol is approved by the human research ethics committee of the University of Nebraska Medical Center. The protocol follows the guidelines of the human research ethics committee of the same university.
1. Insertion of the device
NOTE: This procedure needs to be ideally performed in a fluoroscopy suite to ensure accurate placement of the device.
The device initially gained FDA clearance in the United States after a large randomized control trial, which revealed a 31% improvement in survival in treating acute respiratory distress syndrome with the device used as VV_ECMO22. Eventually, it was approved as a RA to PA bypass. However, the device has not yet been approved for use as an RVAD although at many major centers, the device is already being used as an RVAD substitute in many cases. There are currently ongoing multicenter observati.......
RV shock portends exceptionally high mortality. It should be recognized early in the disease course and treated aggressively. The Protek Duo is a cutting-edge MCS for the treatment of RV shock that can be placed during any of the SCAI stages of shock. A few critical steps in the placement of the device include: obtaining access using the modified Seldinger technique21, sequential dilatation of the access site to appropriate size Fr sheath, floating a balloon-tipped catheter into the main PA, .......
This manuscript would not have been possible without the exceptional support of my mentors, Dr. Poonam Velagapudi and Dr. Anthony Castleberry and support from the entire Cardiovascular and Cardiothoracic Departments at the University of Nebraska Medical Center. No funds were used for the making of this paper.
....Name | Company | Catalog Number | Comments |
Amplatzer Super Stiff Wire 0.035' x 145 cm | Boston Scientific | M001465631 | If not in stock, may use any stiff 0.035" wire. |
Avalon Tracheal Dilator | Avalon Laboratories Inc., Rancho Dominguez, CA | 12210 | This comes in a set. The 30 Fr dilator is the only part used. |
Full 29 Protek Duo Kit | LivaNova/ Tandem Life | 5820-2916 | Cannula, pump, holster, wrap |
Full 31 Protek Duo | LivaNova/Tandem Life | 5820-3118 | Cannula, pump, holster, wrap |
Hemochron Signature Elite ACT Testing Device and Supplies | Werfen North America | DCJACT-A and DCJACT-N | |
Lidocaine | Pharmaceutical | Pfizer | |
LifeSPARC Centrifugal Pump | LivaNova/ Tandem Life | 5840-2417 | |
Micropuncture needle | Cook Medical | G56202 | 5 Fr |
Multi-Lumen Access Catheter | Arrow/Teleflex | AK-21242-CDC | 9 Fr |
Preparation solution | Pharmaceutical | NA | Chlorohexidine-based or iodine-based |
Protek Duo Cannula 29Fr | LivaNova/ Tandem Life | 5140-4629 | Components: One 29 Fr ProtekDuo Veno-Venous Wire Reinforced Cannula with radiopaque tip markers, One 13 Fr Introducer |
Protek Duo Cannula 31Fr | LivaNova/Tandem Life | 5140-5131 | - 31 Fr x 51 cm Veno-Venous Dual Lumen Cannula with Introducer |
Protek Duo Insertion Kit | LivaNova/ Tandem Life | 5100-0014 | Components: balloon tipped PA catheter, one 0.035 stiff guidewire |
Protek Duo RD Cannula | LivaNova/Tandem Life | 5820-3631 | Cannula, introducer |
Swan Ganz Catheter | Edwards Lifesciences | 774F75 or 777F8 | |
Ultrasound | Standard vascular ultrasound. | GE | |
Ultrasound probe cover over the ultrasound transducer | Standard probe cover to match vascular ultrasound transducer | GE | |
Voyager Vest Kit | LivaNova/Tandem Life | Contact LivaNova | Includes vest and wrap. Should not be used on patients with a known allergy to neoprene. |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved